The Impact of Velcade [bortezomib] on Antibody Secreting Cells in Sensitized Renal Allograft Candidates.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2016
At a glance
- Drugs Bortezomib (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 01 Jul 2016 Results published in the Transplantation
- 28 Apr 2016 Treatment arms changed from 1 to 3 with 4, 16 and 32 dose groups.
- 28 Apr 2016 Status changed from active, no longer recruiting to completed.